Frank Dolan

EMA Rejects Eli Lilly's Kisunla: Serious Side Effects Outweigh Benefits in Alzheimer's Treatment

EMA Rejects Eli Lilly’s Kisunla: Serious Side Effects Outweigh Benefits in Alzheimer’s Treatment

Frank Dolan March 30, 2025

DBV Technologies Secures $306 Million for Peanut Allergy Patch: Major Moves in Biotech and Pharma

DBV Technologies Secures $306 Million for Peanut Allergy Patch: Major Moves in Biotech and Pharma

Frank Dolan March 30, 2025

Milestone Pharmaceuticals Faces Setback: FDA Rejects Nasal Spray for Arrhythmia Treatment

Milestone Pharmaceuticals Faces Setback: FDA Rejects Nasal Spray for Arrhythmia Treatment

Frank Dolan March 30, 2025

European Medicines Agency: Breakthroughs and Setbacks in Drug Approvals and Expansions

European Medicines Agency: Breakthroughs and Setbacks in Drug Approvals and Expansions

Frank Dolan March 30, 2025

Johnson & Johnson Triumphs in Patent Battle, Secures Exclusive Rights for Schizophrenia Drug

Johnson & Johnson Triumphs in Patent Battle, Secures Exclusive Rights for Schizophrenia Drug

Frank Dolan March 30, 2025

Revolutionary RNAi Therapy for Hemophilia A and B: FDA Approves Sanofi's Game-Changing Treatment

Revolutionary RNAi Therapy for Hemophilia A and B: FDA Approves Sanofi’s Game-Changing Treatment

Frank Dolan March 30, 2025

Novartis Secures FDA Approval to Expand Pluvicto Use for Prostate Cancer: A Game Changer in Oncology Treatment

Novartis Secures FDA Approval to Expand Pluvicto Use for Prostate Cancer: A Game Changer in Oncology Treatment

Frank Dolan March 30, 2025

Federal Judge Dismisses Amgen's Lawsuit Against Colorado Drug Affordability Board: What It Means for Drug Pricing

Federal Judge Dismisses Amgen’s Lawsuit Against Colorado Drug Affordability Board: What It Means for Drug Pricing

Frank Dolan March 30, 2025

Bluebird Bio Faces Intensifying Competition: Rival Group's New M&A Bid Surpasses Carlyle and SK Capital Offer

Bluebird Bio Faces Intensifying Competition: Rival Group’s New M&A Bid Surpasses Carlyle and SK Capital Offer

Frank Dolan March 30, 2025

Lykos Therapeutics Interim CEO Michael Mullette Steps Down: What's Next for the Company?

Lykos Therapeutics Interim CEO Michael Mullette Steps Down: What’s Next for the Company?

Frank Dolan March 30, 2025

Pandemic Preparedness at Risk: The Impact of COVID Research Funding Cuts on Future Antivirals and Vaccines

Pandemic Preparedness at Risk: The Impact of COVID Research Funding Cuts on Future Antivirals and Vaccines

Frank Dolan March 30, 2025

FDA's Peter Marks Resigns: A Bold Stand Against Misinformation Amid Political Tensions

FDA’s Peter Marks Resigns: A Bold Stand Against Misinformation Amid Political Tensions

Frank Dolan March 30, 2025

Major Shifts in Biopharma: HHS Nominations, Market Challenges, and Key Developments This Week

Major Shifts in Biopharma: HHS Nominations, Market Challenges, and Key Developments This Week

Frank Dolan March 30, 2025

Johnson & Johnson's Legal Triumph: Protecting Schizophrenia Medication from Generic Competition

Johnson & Johnson’s Legal Triumph: Protecting Schizophrenia Medication from Generic Competition

Frank Dolan March 28, 2025

Revolutionizing Lung Cancer Treatment: Merck's Injectable Keytruda Shows Promise in Phase 3 Trials Ahead of FDA Decision

Revolutionizing Lung Cancer Treatment: Merck’s Injectable Keytruda Shows Promise in Phase 3 Trials Ahead of FDA Decision

Frank Dolan March 27, 2025

FDA Approves Cabometyx: A Game-Changer for Advanced Neuroendocrine Tumors

FDA Approves Cabometyx: A Game-Changer for Advanced Neuroendocrine Tumors

Frank Dolan March 26, 2025

Illumina's Board Shake-Up: Activist Investor Keith Meister Joins as Stock Price Plummets 32%

Illumina’s Board Shake-Up: Activist Investor Keith Meister Joins as Stock Price Plummets 32%

Frank Dolan March 25, 2025

Revolutionizing Vaccine Trials: The Role of Disease Transmission Data in Enhancing Efficacy and Safety

Revolutionizing Vaccine Trials: The Role of Disease Transmission Data in Enhancing Efficacy and Safety

Frank Dolan March 24, 2025

BARDA's Annual Industry Day Canceled: What This Means for Biomedical Countermeasures and Pandemic Preparedness

BARDA’s Annual Industry Day Canceled: What This Means for Biomedical Countermeasures and Pandemic Preparedness

Frank Dolan March 21, 2025

Novo Nordisk's Strategic Shift: Boosting Research and Clinical Trial Advancements

Novo Nordisk’s Strategic Shift: Boosting Research and Clinical Trial Advancements

Frank Dolan March 20, 2025

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Insilico Medicine's Third Attempt at an IPO: Aiming Big in Hong Kong's Booming Biotech Market

Insilico Medicine’s Third Attempt at an IPO: Aiming Big in Hong Kong’s Booming Biotech Market

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Insitro Cuts Workforce by 22% Amidst Biotech Industry Challenges: What It Means for the Future of AI in Medicine

Insitro Cuts Workforce by 22% Amidst Biotech Industry Challenges: What It Means for the Future of AI in Medicine

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA